cyrilzakka/clinical-trials huggingface dataset:
The Experience of Older Adults Facing Depression for the First Time in Old Age

Analysis of recent studies show that researchers find it hard to distinguish between Late Onset Depression, a first diagnosed major depressive episode which occurs at old age, and Early Onset Depression, a depressive episode at old age with a history of previous episodes. Since current data, about the phenomenology and etiology of Late Onset Depression, lake conicity it is unclear whether this phenomena should be considered as a distinct subtype of depression. Nevertheless, the wide spread assumption is that Late Onset Depression has a stronger correlation with brain damage and environmental risk factors such as the common losses at old age and weaker correlation with family history and genetics when compared to Early Onset. Although many researchers consider brain damage to have the main contribution to the emerge of Late Onset Depression, the fact that depression has a negative effect on one's health supports the claim that it might be the result and not the rick factor. Since Late Onset Depression correlates with the common losses at old age, the investigators propose that an existential approach that deals with one's meaning, freedom, responsibly and death, might be more appropriate. Thus, the investigators ask how do older adults experience depression which they face for the first time in old age? Current study will seek to understand older adults' experience of Late Onset depression through existential paradigm by using a semi constructed interview.


Eligibility Criteria:
Inclusion Criteria:

1. Men aged 67 or more, women aged 62 or more
2. Diagnosis of Major Depressive Disorder, Minor Depressive Disorder or Adjustment Disorder with depressive features made after the age of 67 with men and 62 with women.
3. Basic understanding and ability to converse in Hebrew.

Exclusion Criteria:

1. History of at least one previous major depressive or minor depressive episode before the age of 62 with women or 67 with men
2. Mental Retardation or Autistic Spectrum Disorder
3. Significant cognitive impairment observed by the primary physician.
4. Schizophrenia or Schizoaffective disorder.
5. Depressive episode with psychotic features
6. Substantial suicidality
Usage of Multiple Drugs in Treatment of Postoperative Vomiting After Laparoscopic Appendectomy

To compare and evaluate the antiemetic effect and the safety of ondansetron, inhalational isopropyl alcohol and super hydration on adult patients after laparoscopic appendectomy.

This prospective double-blind study done on 240 patients admitted to surgical I.C.U after laparoscopic appendectomy. Those who had preoperative Koivuranta vomiting score of more than 3 enrolled in our study. Every group contains 80 patients. Patients of group A received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group B received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours. The last group C received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours. The duration of the study was 24 hours post-operatively. As PONV is self-limited within 24 hours.

Eligibility Criteria:
Inclusion Criteria:

postoperative nausea and vomiting

Exclusion Criteria:

systemic disease as diabetes or hypertension local gastric diseases
Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival

This randomized clinical trial aims to compare the effectiveness of heparin alone versus combination therapy of Heparin- Aspirin in improving free flap survival in patients undergoing reconstructive surgery. Participants will be randomly assigned to receive either heparin or a combination therapy, and the primary outcome measure will be the survival rate of the free flap at various time points post-surgery

The objective of this randomized clinical trial is to evaluate the efficacy of heparin alone vs compared to combination therapy of Heparin-Aspirin in enhancing free flap survival in patients undergoing reconstructive surgery. Participants will be randomly assigned to one of two groups: one receiving standard heparin therapy and the other receiving a combination therapy that includes heparin and other agents. The primary outcome will be the survival rate of the free flap, assessed at multiple intervals after surgery. Secondary outcomes will to assess the incidence of flap thrombosis, bleeding complications, re-operation in free flap surgeries and overall patient outcomes in both groups. Ethical approval will be obtained, and informed consent will be required from all participants. This trial seeks to provide robust evidence on the potential benefits of combination therapy over heparin alone in free flap survival, potentially informing future clinical guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing free flap surgery
* Age between 18 and 70 years

Exclusion Criteria:

* Known hypersensitivity to heparin or aspirin
* History of bleeding disorders
* Concurrent use of other anticoagulant or antiplatelet medications
* Severe renal or hepatic impairment
* Preoperative use of aspirin that could not be stopped five days before surgery due to a higher risk of cardiac-related complications.
Evaluating a Noise Reduction Algorithm With Cochlear Implant Users

In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.


Eligibility Criteria:
Inclusion Criteria:

* At least 12 years of age.
* Be post-lingually deafened cochlear implant recipients with at least 6 months experience regardless of manufacturer.
* The PI must also deem the child to be developmentally able to complete the experiments.

Exclusion Criteria:

• Anyone who is not a cochlear implant user or is aged under 12 years.
Novel Approach to Assess Metabolic Flexibility in a Respiratory Chamber

The overarching aim of this study: To determine the effect of different meal compositions (high- vs. low-fat) on metabolic flexibility as it relates to meal-stimulated change in respiratory quotient (ΔRQ1) and sleep (ΔRQ2) metabolic flexibility, as well as the time course changes in respiratory quotient, RQ (i.e., peak RQ, time to peak RQ, nadir RQ, time to nadir, slope).


Eligibility Criteria:
Inclusion Criteria:

* Eligibility criteria include:

  * Healthy male or female
  * Ages 18-40 y
  * BMI between 20 kg/m2 and 30 kg/m2 (±0.5 kg/m2 will be accepted)
  * Are willing to consume pre-prepared meals
  * Are willing to maintain current physical activity, sleep schedule, and dietary habits during the study.
  * Medically cleared for participation in the study by Medical Investigator

Exclusion Criteria:

* Participants are ineligible to participate (or will be excluded from participating in this study) if they meet any of the following criteria:

  * Unstable weight in the last 3 months \[gain or loss \>7 lb (or 3.2 kg)\]
  * Currently working shift work
  * Smoking or use of tobacco products within the last 3 months
  * Amenorrhea (or absence of regular monthly cycles)
  * History of clinically diagnosed diabetes or a fasting blood glucose \>126 mg/dL
  * Average screening blood pressure \>140/90 mmHg
  * Previous bariatric surgery (or other surgeries) for obesity or weight loss
  * Use of medications affecting metabolism or sleep
  * History of neurological disease
  * History of cardiovascular disease (or other chronic diseases)
  * Pregnant, planning to become pregnant, or breastfeeding
  * Adherence to special restrained diets (e.g., low-carbohydrate, low-fat, or vegetarian/vegan diets) over the last 3 months.
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.

Upon determination of eligibility all patients will receive:

* Docetaxel + Gemcitabine + Cetuximab

Eligibility Criteria:
Inclusion Criteria:

To be included in the study, you must meet the following criteria:

* 18 years of age or older
* Non-small cell lung cancer confirmed by biopsy
* Unresectable stage III or IV disease
* Measurable disease
* Must not have received any prior chemotherapy for lung cancer
* Able to perform activities of daily living without considerable assistance
* Adequate bone marrow, kidney, and liver function
* Signed informed consent

Exclusion Criteria:

You cannot participate in the study if any of the following apply to you:

* History of serious heart disease within six months prior to study entry
* Prior treatment with agents that target the EGFR pathway
* History of any other uncontrolled or significant disease

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.
Gastroparesis Outcome Longitudinal Database Enrolled Numerically

GOLDEN is a longitudinal database of patients with the symptoms (Sx) of gastroparesis (Gp) who were seen and recorded at the University of Louisville from 2012 and is ongoing. Patients are enrolled and followed by sequential numbers and may include legacy patients seen at other centers by some of the same team and who are reported as part of the series. Outcome relate to patients Sx, survival, quality of life and other measures as detailed below, over time, regardless of whether any treatment was given or not. If treatments were administered GOLDEN allows for examination and stratification of outcome by groups both at baseline and at follow up.

1. All patients seen with the Sx of Gp and who were evaluated for diagnosis and/or treatment
2. Including legacy patients who were seen and treated at previous locations (Mississippi, Arkansas, Tennessee) before Kentucky if they were part of a clinical research series.
3. Numbers of patients referred or consulted for Gp Sx who were Drug Refractory.
4. Interventions: GI Neuromodulation with gastric electrical stimulation (GES); Immunotherapy with Intravenous Immunoglobulin; Pyloric therapies such as pyloroplasty, surgical or endoscopic.
5. Data for evaluation by: Sx assessments by whatever scales used; Measures of health related quality of life; Psychological and pain assessments; Gastric emptying texts; Electrical measures; Autonomic measure; Serologic measures; Full thickness biopsies; Measures of outpatient \& Emergency Room Visits; Measures of hospitalization; Placement of endoscopic or surgical tubes; Radiological and Surgical procedures; Nutritional assessments; If enrolled in any research protocols for data; Stool biome measures; Metabolic measures; Other morbidity measures; Mortality

Eligibility Criteria:
Inclusion:

* Patients with the symptoms (Sx) of drug refractory gastroparesis
* Disordered nutrition by standardized assessment
* Ability to assess current symptom status
* Ability to measure other medical conditions

Exclusion:

* Anatomic obstruction of the GI Tract
* Pregnancy
* Inability of patient or guardian to sign informed consent, if needed
* Psychiatric disorders precluding assessment and treatment of the patient's GI condition
Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke

To evaluate the effect of the dynamic combination therapy on Chinese herbal granule formula (Fangji) based on differentiation of syndromes ("Zhenghou") according to the theory of traditional Chinese medicine for improving the symptoms in the convalescent phase of ischemic stroke, and to establish the pharmacodynamic model of "Zhenghou" according to the results of this trial.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18 - 75 years.
* Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect, confirmed by CT or MRI scan.
* Clinical diagnosis of "Qixu-Xueyu Zheng" (Qi deficiency and Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales in ischemic stroke on both "Qixue" and "Xueyu" ≥ 7.
* 15 days to 60 days after onset of symptoms.
* Clinical diagnosis of cerebral anterior circulation obstruction.
* 4≤NIHSS\<20.
* Patient is willing to participate voluntarily and to sign a written patient informed consent.

Exclusion Criteria:

* Transient ischemic attack
* Evidence of intracranial hemorrhage (ICH) in 6 months
* Evidence of other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT or MRI scan.
* Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
* Woman who is under menstrual period.
* Known history of allergy or suspected allergic to these chinese herbs.
* Complicated with atrial fibrillation.
* Fasting blood glucose ≥8 mmol / l under the treatment of diabetes or complicated with severe cardio-cerebrovascular diseases (eg. hyperlipemia, coronary heart disease with angina attack ≥ 4 times a day).
* Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
* Renal dysfunction with the value of serum creatinine over normal value.
* Prior disable patients or complicated with osteoarthropathy that influence the motor function of the limbs.
* With mental disorder that can not cooperate with doctor
* Suspected addicted into alcohol or drug abuse.
* With severe complications that would make the condition more complicated assessed by the investigator.
* Patient who is participating in other trials or has been participated in other trials in recent 3 months.
Effects of Sarcopenia on General Health Status in Elderly: a Population-based Study

This is a observational study, that aimed to determine the prevalence of sarcopenia using European Wording Group on Sarcopenia in Older People (EWGSOP) algorithm in a general elderly population in Algarve region (Portugal). Because muscle is metabolically active tissue, sarcopenia may also contribute to the development of some of the metabolic disorders associated with aging. However, the risk factors associated with sarcopenia are poorly understood. Thus, a cross-sectional survey of a sample of 274 elderly adults aged 60 or over, were included in the study. Correlations of sarcopenia with functional level, lipid and glycemic profile, nutritional and physical activity level, fall risk, quality of life, and self-reported comorbidities will be studied.


Eligibility Criteria:
Inclusion Criteria:

* Minimum age of 60 years;
* Live in the community;
* Independet Gait.

Exclusion Criteria:

* Presence of moderate or severe cognitive impairment;
* Presence of uncontrolled cardiovascular disease and active cancer;
* Use of a pacemaker;
* Use of internal prosthesis.
Heart Rate Variability and Stress Management Enhancement

This study will be conducted by using two devices (Apollo and Biostrap) for monitoring of baseline physiologic variables and heart rate variability. The biostrap will be worn by residents and will monitor heart rate, heart rate variability, respiratory rate, sleep patterns, steps, etc. The Apollo is a pulse generator device aimed at modulating heart rate variability for (hopefully) reduction in stress and improving performance in and around the hospital. Resident neurosurgeons will wear the biostrap for a two week cycle and follow that with the addition of the Apollo device for heart rate variability modulation.


Eligibility Criteria:
Inclusion Criteria:

* Neurosurgical Resident (UPMC)

Exclusion Criteria:

* None
Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).


Eligibility Criteria:
Key Inclusion Criteria:

* Willing and able to give informed consent prior to any study specific procedures being performed. In individuals with hepatic encephalopathy (HE) which may impair decision-making, consent will be obtained per hospital procedures (eg, by Legally Authorized Representative)
* Clinical diagnosis of severe AH

  * Maddrey's Discriminant Function (DF) ≥ 32 at screening

Key Exclusion Criteria:

* Pregnant or lactating females;
* Other causes of liver disease including chronic hepatitis B (hepatitis B surface antigen \[HBsAg\] positive), chronic hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease;
* Serum aspartate aminotransferase (AST) \>400 U/L or alanine aminotransferase (ALT) \>300 U/L;
* Model for End Stage Liver Disease (MELD) \>30 at screening;
* Maddrey's DF \>60 at screening;
* Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria;
* Concomitant or previous history of hepatocellular carcinoma;
* History of liver transplantation;
* HIV Ab positive;
* Clinical suspicion of pneumonia;
* Uncontrolled sepsis;
* Uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of screening that was associated with shock or required transfusion of more than 3 units of blood;
* Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine \>221 μmol/L (\>2.5 mg/dL) or the requirement for renal replacement therapy;
* Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory support (ie, endotracheal intubation or positive-pressure ventilation);
* Portal vein thrombosis;
* Acute pancreatitis;
* Cessation of alcohol consumption for more than 2 months before Baseline/ Day 1

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF)

The low-level laser therapy (LLLT) has been used in many inflammatory disorders. More recently the LLLT was associated with an improvement in the muscle strength and endurance. But, these effects were described only in health or athletic individuals. In this randomized and controlled clinical trails, the investigators will study the effects of LLLT on muscle strength of the patients with kidneys failure on long time hemodialysis treatment. Additionally, investigators will explore three different intensities up the muscle strength.

This study will be conducing in a large hospital that is reference in kidneys disorders treatments. 16 patients will be randomized for placebo, 4J, 6J, or 8J low-level laser therapy (LLLT). The maximal voluntary contraction (MVC) will be test by handgrip test before and after de LLLT. One-week interval between the LLLT will gave to reduce the influence between the treatments. Moreover the endurance test will be use to evaluate the muscle oxidation impact of the LLLT.

Eligibility Criteria:
Inclusion Criteria:

* chronic kidney failure,
* long time hemodialysis treatment (\>18 months)

Exclusion Criteria:

* any health disturbance that can reduces the handgrip test performance beyond to the produced by the chronic kidney failure.
Physiotherapy Intervention in Climacteric Women With Dyspareunia

Aim: To evaluate the effectiveness of physical therapy intervention techniques in the improvement of dyspareunia in climacteric women.

Study design: This is a randomized controlled trial.

Search location: Menopause and Sexuality Clinic of the department of obstetrics and Gynecology and Clinical Research Center, Hospital de Clínicas de Porto Alegre (HCPA).

Patients or participants: The recruited patients may not be vaginal atrophy (cytology-hormone test) and must provide the diagnosis of dyspareunia for more than six months being confirmed by one of the investigators through the pain score above grade 3 (visual analog pain scale) visual inspection, palpation and a questionnaire about the duration and location of pain.

Intervention and measures: consist of evaluation of the pelvic floor muscles (Oxford Scale and Perfect), myoelectric assessment (Electromyography), quality of life (Cervantes Scale), sexual function (FSFI), level of depression (Beck Scale) and pain (visual analog pain scale) before and after physical therapy intervention.

Expected results: To estimate the effectiveness of pelvic floor training techniques with physical therapy in women with dyspareunia.

Eligibility Criteria:
Inclusion Criteria:

* dyspareunia complaint for at least six months
* visual analog scale of pain above 3
* trophic vagina

Exclusion Criteria:

* vaginal atrophy
* neurological disorders
* lack of cognition and understanding
* urinary tract infection and / or genital infections
* prolapse grade 2 and 3
* severe systemic disease
* performing physical therapy
Effect of Photodynamic Therapy on Soft Tissue Healing After Tooth Extraction at Sites of Periodontal Infection

Main Purpose: To evaluate the effect of photodynamic therapy on soft tissue healing after tooth extraction at periodontal infection site, and to compare the effect on pain degree and bone tissue remodeling after tooth extraction.

The aim of this study is to evaluate the effect of photodynamic therapy (PDT) on soft tissue healing and bone remodeling in tooth extraction sockets after tooth extraction. The enrolled patients will be randomized into two groups. The control group used conventional tooth extraction to clean the wound, and the experimental group used photodynamic therapy to help clean the wound. Seven days and 14 days after extraction, the area of extraction socket was measured, the healing rate of extraction socket was calculated, and Landry, Turnbull and Howley soft tissue healing index was measured. The degree of pain was recorded at 6h, 1 day, 2 days and 3 days after tooth extraction. Bone remodeling indexes were measured at 1 month after tooth extraction.

Eligibility Criteria:
Inclusion Criteria:

* Age range from 18 to 65 years old;
* Patients with extensive periodontitis of the whole mouth;
* There was a deep periodontal pocket with PD≥5mm and at least one adjacent tooth at the extraction site;
* Periodontitis was controlled, and the extraction site and adjacent teeth were not in the acute inflammation or infection stage;
* The extraction site has a hopeless prognosis or no preservation value, and it is the first and second molars or maxillary wisdom teeth that erupt in a positive position

Exclusion Criteria:

* pregnant and lactating women;
* patients with systemic diseases that may affect the ability of postoperative healing (such as patients with radiotherapy and chemotherapy, history of hematological diseases, and uncontrolled disease) Diabetes mellitus, etc.);
* long-term use of drugs known to affect bone metabolism or mucosal healing such as bisphosphonates and non-steroidal anti-inflammatory drugs;
* smoking \> 10 cigarettes per day;
* root breakage or gingival tear occurred during tooth extraction.